Compare · CERS vs PDD
CERS vs PDD
Side-by-side comparison of Cerus Corporation (CERS) and PDD Holdings Inc. (PDD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CERS and PDD operate in EDP Services (Technology), so they compete in similar markets.
- PDD is the larger of the two at $117.66B, about 200.4x CERS ($587.1M).
- Over the past year, CERS is up 116.2% and PDD is down 29.1% - CERS leads by 145.3 points.
- CERS has hit the wire 3 times in the past 4 weeks while PDD has been quiet.
- PDD has more recent analyst coverage (25 ratings vs 4 for CERS).
- Company
- Cerus Corporation
- PDD Holdings Inc.
- Price
- $2.94+2.08%
- $82.71-0.74%
- Market cap
- $587.1M
- $117.66B
- 1M return
- +11.57%
- +9.23%
- 1Y return
- +116.18%
- -29.14%
- Industry
- EDP Services
- EDP Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1997
- 2018
- News (4w)
- 3
- 0
- Recent ratings
- 4
- 25
Cerus Corporation
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation has collaboration with LifeSouth Community Blood Centers to manufacture INTERCEPT Fibrinogen Complex. The company was incorporated in 1991 and is headquartered in Concord, California.
PDD Holdings Inc.
Pinduoduo Inc., through its subsidiaries, operates an e-commerce platform in the People's Republic of China. It operates Pinduoduo, a mobile platform that offers a range of products, including apparel, shoes, bags, mother and childcare products, food and beverage, fresh produce, electronic appliances, furniture and household goods, cosmetics and other personal care items, sports and fitness items, and auto accessories. The company was formerly known as Walnut Street Group Holding Limited and changed its name to Pinduoduo Inc. in July 2018. Pinduoduo Inc. was incorporated in 2015 and is headquartered in Shanghai, the People's Republic of China.
Latest CERS
- Chief Executive Officer Jayaraman Vivek K sold $52,665 worth of shares (16,666 units at $3.16) as part of a pre-agreed trading plan, decreasing direct ownership by 0.74% to 2,232,211 units (SEC Form 4)
- Cerus Corporation to Release Second Quarter 2026 Financial Results on July 30, 2026
- Cerus Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Chief Financial Officer Green Kevin Dennis sold $99,105 worth of shares (33,676 units at $2.94) as part of a pre-agreed trading plan and gave a grant of 63,600 shares, decreasing direct ownership by 8% to 1,062,188 units (SEC Form 4) to cover withholding tax
- Chief Operating Officer Jayaraman Vivek K was granted 554,529 shares, gave a grant of 80,000 shares and sold $124,658 worth of shares (42,359 units at $2.94) as part of a pre-agreed trading plan, increasing direct ownership by 24% to 2,248,877 units (SEC Form 4) to satisfy withholding obligation
- Chief Legal Officer Jensen Chrystal gave a grant of 55,000 shares and sold $71,598 worth of shares (24,329 units at $2.94) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 966,657 units (SEC Form 4) (for withholding tax)
- President and CEO Greenman William Mariner gave a grant of 192,500 shares and sold $299,937 worth of shares (101,919 units at $2.94) as part of a pre-agreed trading plan, decreasing direct ownership by 6% to 5,053,036 units (SEC Form 4) to cover taxes
- Cerus to Showcase New Evidence, Innovation and Global Experience with the INTERCEPT Blood System at the 39th International ISBT Congress
- Director Bjerkholt Eric sold $53,180 worth of shares (20,454 units at $2.60), decreasing direct ownership by 7% to 261,679 units (SEC Form 4)
- Cerus Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation
Latest PDD
- SEC Form 4 filed by Co-Chief Executive Officer Zhao Jiazhen
- SEC Form 4 filed by SVP of Engineering Wang Mi
- PDD Holdings downgraded by Daiwa Securities with a new price target
- BNP Paribas Exane initiated coverage on PDD Holdings with a new price target
- PDD Holdings downgraded by Macquarie with a new price target
- PDD Holdings downgraded by Barclays with a new price target
- SEC Form 6-K filed by PDD Holdings Inc.
- PDD Holdings Announces First Quarter 2026 Unaudited Financial Results
- PDD Holdings to Report First Quarter 2026 Unaudited Financial Results on May 27, 2026
- SEC Form 20-F filed by PDD Holdings Inc.